• 9430 Key West Avenue Rockville, MD 20850 I (240) 268.1141

About Cellphire


Overview

Cellphire, Inc. is a biotechnology company established in early 2006. The company focus is on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets through its proprietary cutting edge cell stabilization technology. With its origins in bio-defense, Cellphire is commercializing freeze dried platelet derived products with an initial focus on applications within the global blood & blood supply markets.

Cellphire is developing technology and products with application in diverse health care fields from transfusion, advanced wound care (chronic & acute) to clinical & research diagnostic reagents.

The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or manmade disasters would interrupt the constant supply of platelets that is needed to maintain an adequate supply or treat bleeding casualties.

Message from the CEO:

The underlying technology that Cellphire has developed promises to provide a quantum leap forward in how cells are handled and used within health care today. Our initial application, platelets, is a perfect example. Untreated platelets last five days outside of a donor’s body: with our patented treatment, we are able to freeze dry platelet derived products for storage measured in years, at room temperature. Reconstitution is as simple as adding sterile water.

With the support of the Biomedical Advanced Research Defense Authority (BARDA), a division of U.S. Department of Health & Human Services, and their $57 million grant to us, we have the ability and resources to take this product far down the road through a Phase 2 clinical trial and eventually FDA approval. BARDA is interested because this product has the potential to be the first and only product to remediate a key problem caused by exposure to radiation. Our reconstituted freeze dried platelets (Thrombosomes®) have been shown, in animals, to have profound benefits in wound healing. Thromobosomes® have the potential to be powerful imaging agents; to assist in sports medicine, plastic surgery, dentistry; as well as a host of other applications. Our underlying cell stabilization technology has application to other cell types as well.

Our fundamental mission is to obtain FDA approval of Thrombosomes® as a hemostatic agent to stop active bleeding in surgical or thrombocytopenic patients while BARDA’s interest is in the use of Thrombosomes® for treatment of acute radiation sickness. We can pursue other applications as well, because the same technology is used in each of them. To do them as well, we will seek additional partners in each related field. By continuing our unique ability to stabilize cells with leading companies in key therapeutic areas, we seek to make a major difference in health care in the United States and around the world.

Sincerely,
Stephen H Willard
CEO

cellphire-img

Leadership


Management:

Stephen H Willard - CEO
Mr. Willard joined Cellphire as its CEO at the end of 2013. He was previously CEO of Flamel Technologies, S.A., a NASDAQ-traded biotech company for seven years and served as CFO prior to becoming CEO. He was the former Chairman of the Board of Directors of Flamel and served on the Board of Directors of E*Trade Financial Corporation. Mr. Willard received a Bachelor of Arts degree from Williams College and a Juris Doctorate from Yale Law School.

G. Michael Fitzpatrick - Ph.D., President & Director of R&D
Mike has been at Cellphire since 2007 and has led the R&D efforts to develop clinical applications of its first line of products. He comes to Cellphire from his previous position with America's Blood Centers as its Chief Operating Officer, prior to that Mike was a Colonel in the US Army and the Director of the Armed Services Blood Program Office.

Richard O Cliff - Co-Founder & V.P. of Operations
Richard O. Cliff (co-founder, VP, COO): Richard has over 25 years’ experience in R&D government contracting both in technical and business roles. His background also includes management of intellectual property, corporate finances, human resources and operations management. He has been involved in biotech/life science start-up and early growth enterprises for the past 12 years as the CEO of Adlyfe and previously as an affiliate Associate Professor with George Mason University. Richard has a BS degree in Biology from the George Washington University and an Executive Masters in Technology Management from the School of Engineering and the Wharton Business School at the University of Pennsylvania.


Mike Stanton - Chief Operating Officer
Mike Stanton has been at Cellphire since Jan 2014. His background includes extensive experience in both blood bank administration with strong technical, regulatory and quality skills, and in clinical information systems, to include Quality System Regulations, medical device 510(k) development and submission, as well as Management Representative for medical device manufacturing. Mike was a Lieutenant Colonel in the US Army.  He is a registered Medical Technologist with a Specialist in Blood Bank certification and holds a Bachelor of Science degree from University of Illinois Chicago and a Master of Science Degree from the University of Cincinnati, College of Medicine.

Thomas Landro - Director of Program Management
Thom Landro is the Director of Program Management at Cellphire and is the Program Manager for Cellphire’s BARDA contract for the development of Thrombosomes®. Mr. Landro joins Cellphire after 15 years of program, portfolio and alliance management experience in the pharmaceutical, biotech, and medical device industries. Recent experience includes serving as Director of Strategic Technical Alliances at Novavax, Inc. and was the Program Manager for Medimmune’s BARDA contract for the development of Cell Culture Derived Seasonal and Pandemic Influenza Vaccines. Thom is PMP Certified and holds a Bachelor of Science in Chemical Engineering at the University of Utah and an MBA from the University of Michigan.

Nigel J McWilliam - VP Business Development
Nigel McWilliam,VP of Business Development. Before joining Cellphire he was V.P.Business Development of Flamel Technologies, Inc (FLML on the Nasdaq). From 1999 to 2003 he established a business development group in the USA and Japan for SkyePharma as Senior VP Business Development. His career began with 18 years with Dow Corning Corporation in commercial roles within their health care businesses in the UK, Belgium, France, before moving to DCC’s headquarters in Midland, MI in 1988. He is a graduate of the Dundee University, Scotland, B.Sc. Physiology & Psychology.

Ruth Biehl - Quality Assurance Director
Ruth Biehl has been at Cellphire since November 2013. Her early experience encompassed clinical laboratory testing, genetic engineering research, and operations research.  Since 1990 she has focused on FDA compliance remediation, quality systems design and implementation, quality systems auditing, establishing procedures for drug and medical device manufacturer’s management of clinical trials, and monitoring clinical trials.  She is a registered Clinical Laboratory Scientist (ASCP) and licensed Medical Laboratory Scientist (California).  She is certified by ASQ as a Manager of Quality/Organizational Excellence and as a Quality Engineer.  She is certified by the Association of Clinical Research Professionals as a Certified Clinical Research Associate (CCRA).  Ruth is also an IRCA-certificated ISO 9000 quality management systems auditor.  She holds a Bachelor of Science degree from Oregon State University, a Master of Science from the University of Arizona, and a Master of Business Administration from Southern Illinois University at Edwardsville.

Dr. Giora Feuerstein, MD, MSc, FAHA - Director of Discovery Research
Dr. Giora Feuerstein shares his time as the Chief Medical Officer of the Chem/Bio Division of the U.S. Defense Threat Reduction Agency.  He was formerly Head of Discovery Translational Medicine, Wyeth Research. Before joining Wyeth, Dr. Feuerstein held Directorship positions in discovery of cardiovascular, stroke, thrombosis, inflammation and metabolic disease programs for 16 years at SmithKline Beecham, DuPont Pharmaceuticals and Merck. With his additional background in platelet biology and history with Cellphire, almost since its inception, Dr. Feuerstein’s role directing early discovery and research is a natural fit.

BOARD OF DIRECTORS:

John Ludwig Vogelstein (Chairman)
Mr. John Ludwig Vogelstein serves as a Special Limited Partner, Managing Director, Senior Advisor, and Vice Chairman of Warburg Pincus LLC. He joined Warburg Pincus in 1967 shortly after its founding and has been in the investment business for 60 years.


Stephen H Willard, CEO
Mr. Willard joined Cellphire as its CEO at the end of 2013. He was previously CEO of Flamel Technologies, S.A., a NASDAQ-traded biotech company for seven years and served as CFO prior to becoming CEO. He was the former Chairman of the Board of Directors of Flamel and served on the Board of Directors of E*Trade Financial Corporation. Mr. Willard received a Bachelor of Arts degree from Williams College and a Juris Doctorate from Yale Law School.

James B. Peake, MD
Jim is the former Secretary of Veterans Affairs, he is a retired U.S. Army Lieutenant General and served as the Army Surgeon General, in addition he was the Executive Vice President and Chief Operating Officer of Project Hope

Rodman W. Moorhead III
Mr. Moorhead retired from Warburg Pincus, a global private equity firm, after a career spanning 37 years. His last position at Warburg Pincus was as Senior Advisor and Managing Director of their Life Sciences practice. He is Chairman of the Board of The Taft School, a member of the Harvard Medical School Board of Fellows, Chairman of Stroud Water Research Center, trustee of the Brandywine Conservancy and trustee of the Jackson Hole Land Trust. Mr. Moorhead holds an AB in Economics from Harvard College and an MBA from Harvard Business School.

 

SCIENTIFIC ADVISORY BOARD

Dr. Giora Feuerstein, former VP Wyeth Research (Pfizer)
Dr. John Crowe, Professor Emeritus UC-Davis
Dr. Tim Hannon, Medical Director Blood Management Program, St. Vincent’s Hospital
Dr. Steven Gould, former CEO Northfield

Have Questions?Reach us here

Please enter your information below

The Cellphire Method

Cellphire has developed a proprietary method for the stabilization of blood in the dry state. First application of this technology will be the long term stabilization of blood platelets (freeze-dried platelets).